References of "Cephalalgia : An International Journal of Headache"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailOne-year Prevalence of Migraine Using a Validated Extended French Version of the ID MigraineTM: a Belgian Population-Based Study
Schoenen, Jean ULg; Streel, Sylvie ULg; Donneau, Anne-Françoise ULg et al

in Cephalalgia : An International Journal of Headache (2015, May), 35(6), 155-156

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailTargeting pericranial nerve branches to treat migraine: Current approaches and perspectives.
Ambrosini, Armin; D'Alessio, Costantino; MAGIS, Delphine ULg et al

in Cephalalgia : An International Journal of Headache (2015)

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailValidation of an extended French version of ID MigraineTM as a migraine-screening tool
Streel, Sylvie ULg; Donneau, Anne-Françoise ULg; Dardenne, Nadia ULg et al

in Cephalalgia : An International Journal of Headache (2015), 35(5), 437-442

Introduction: Migraine has a considerable social, economic, physical and emotional burden but remains underdiagnosed and undertreated. A specific migraine screening tool could help remove barriers to ... [more ▼]

Introduction: Migraine has a considerable social, economic, physical and emotional burden but remains underdiagnosed and undertreated. A specific migraine screening tool could help remove barriers to health care and be an attractive instrument for epidemiological studies. The objective of this work was to assess the validity of an extended French version of ID MigraineTM as a migraine-screening tool. Methods: Sixty-seven subjects from the NESCaV study (2010–2012) completed the migraine screen and were diagnosed by a neurologist specializing in headache medicine using the International Classification of Headache Disorders, 2nd edition criteria (gold standard). Agreement between the two diagnoses was evaluated by Cohen kappa coefficient (k). Sensitivity, specificity and predictive values of the migraine screen were calculated. Results: Migraine was diagnosed in 21 (31.3%) of the 67 subjects according to the screening tool and in 24 (35.8%) by the neurologist (k¼0.90). The prevalence of migraine was unrelated to age, gender, education and perception of financial resources. Sensitivity and specificity of the screen were 87.5% and 100%, respectively. The screen prevalence of migraine with aura was 10.4% (sensitivity and specificity: 83.3% and 96.7%, respectively). Conclusion: The extended French version of ID MigraineTM (ef-ID Migraine) is a validated tool to screen migraine in French-speaking countries. [less ▲]

Detailed reference viewed: 37 (22 ULg)
Full Text
Peer Reviewed
See detailSphenopalatine ganglion neuromodulation in migraine: What is the rationale?
SCHOENEN, Jean ULg; Khan, S; Ashina, M

in Cephalalgia : An International Journal of Headache (2014), 34(5), 382-391

This article examines the pathophysiological facets of migraine that would made the disorder amenable by sphenopalatine ganglion neurostimulation.

Detailed reference viewed: 53 (2 ULg)
Full Text
Peer Reviewed
See detailMigraine and serotonin: The quest for the Holy Grail goes on.
SCHOENEN, Jean ULg

in Cephalalgia : An International Journal of Headache (2014), 34(3), 163-164

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailPrevalence of right-to-left shunts on transcranial Doppler in chronic migraine and medication-overuse headache.
Guo, Song; SCHOENEN, Jean ULg

in Cephalalgia : An International Journal of Headache (2014), 34(1), 37-41

The prevalence of right-to-left shunts on transcranial Doppler is not increased in chronic migraine.

Detailed reference viewed: 27 (5 ULg)
Full Text
Peer Reviewed
See detailPearls and pitfalls: Electrophysiology for primary headaches
MAGIS, Delphine ULg; Vigano, Alessandro; SAVA, Simona Liliana ULg et al

in Cephalalgia : An International Journal of Headache (2013)

Detailed reference viewed: 53 (5 ULg)
Full Text
Peer Reviewed
See detailStimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: A randomized, sham-controlled study.
Schoenen, Jean ULg; Jensen, Rigmor Hojland; Lanteri-Minet, Michel et al

in Cephalalgia : An International Journal of Headache (2013)

BackgroundThe pain and autonomic symptoms of cluster headache (CH) result from activation of the trigeminal parasympathetic reflex, mediated through the sphenopalatine ganglion (SPG). We investigated the ... [more ▼]

BackgroundThe pain and autonomic symptoms of cluster headache (CH) result from activation of the trigeminal parasympathetic reflex, mediated through the sphenopalatine ganglion (SPG). We investigated the safety and efficacy of on-demand SPG stimulation for chronic CH (CCH).MethodsA multicenter, multiple CH attack study of an implantable on-demand SPG neurostimulator was conducted in patients suffering from refractory CCH. Each CH attack was randomly treated with full, sub-perception, or sham stimulation. Pain relief at 15 minutes following SPG stimulation and device- or procedure-related serious adverse events (SAEs) were evaluated.FindingsThirty-two patients were enrolled and 28 completed the randomized experimental period. Pain relief was achieved in 67.1% of full stimulation-treated attacks compared to 7.4% of sham-treated and 7.3% of sub-perception-treated attacks (p < 0.0001). Nineteen of 28 (68%) patients experienced a clinically significant improvement: seven (25%) achieved pain relief in >/=50% of treated attacks, 10 (36%), a >/=50% reduction in attack frequency, and two (7%), both. Five SAEs occurred and most patients (81%) experienced transient, mild/moderate loss of sensation within distinct maxillary nerve regions; 65% of events resolved within three months.InterpretationOn-demand SPG stimulation using the ATI Neurostimulation System is an effective novel therapy for CCH sufferers, with dual beneficial effects, acute pain relief and observed attack prevention, and has an acceptable safety profile compared to similar surgical procedures. [less ▲]

Detailed reference viewed: 25 (2 ULg)
Full Text
Peer Reviewed
See detailQuadripulse Repetitive Transcranial Magnetic Stimulation on Visual Cortex for Chronic Migraine Prevention: A Pilot-Trial
Sasso d'Elia, Tullia; Vigano, Alessandro; Fataki, Michel et al

in Cephalalgia : An International Journal of Headache (2013), 33(8), 49

Detailed reference viewed: 43 (1 ULg)
Full Text
Peer Reviewed
See detailA novel CACNA1A mutation results in episodic ataxia with migrainous features without headache
MAGIS, Delphine ULg; Boon, Elles; Coppola, Gianluca et al

in Cephalalgia : An International Journal of Headache (2012)

Detailed reference viewed: 19 (1 ULg)
Full Text
Peer Reviewed
See detailEffects of repetitive transcranial magnetic stimulation on somatosensory evoked potentials and high frequency oscillations in migraine.
Coppola, Gianluca; De Pasqua, Victor; Pierelli, Francesco et al

in Cephalalgia : An International Journal of Headache (2012), 32(9), 700-9

Background: In previous studies we found that high-frequency somatosensory oscillations (HFOs) reflecting thalamo-cortical activation were decreased in migraineurs between attacks and that high-frequency ... [more ▼]

Background: In previous studies we found that high-frequency somatosensory oscillations (HFOs) reflecting thalamo-cortical activation were decreased in migraineurs between attacks and that high-frequency repetitive transcranial magnetic stimulation (rTMS) was able to normalize the habituation deficit of visual evoked potentials (VEPs). Here we study the effects of activating (10 Hz) or inhibiting (1 Hz) rTMS on conventional low-frequency (LF) and high-frequency somatosensory evoked potentials (SSEPs). Subjects and methods: rTMS was applied on the motor cortex of 13 healthy volunteers (HVs) and 13 migraine without aura (MO) patients. We measured N20-P25 LF-SSEP amplitude and habituation, and maximal peak-to-peak amplitude of early and late HFOs before and after rTMS. Results: In HVs, 1 Hz rTMS significantly reduced the amplitude of the first LF-SSEP block and its habituation. In MO patients, 10 Hz rTMS increased the amplitude of the first block and induced habituation. Ten Hz rTMS produced an increase of late HFO in both groups, but more interestingly, in MO patients also significantly increased the early HFOs, which are reduced at baseline compared to those of HVs. Conclusions: These data confirm for SSEP that excitatory rTMS can normalize habituation in migraine patients and show that this is accompanied by early an HFO increase, which is thought to reflect thalamo-cortical activity. Taken together with similar effects we observed for VEPs, this finding supports the hypothesis that dysfunctioning thalamo-cortical loops may be responsible for the interictal habituation deficit in migraine. [less ▲]

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailDrug-induced changes in cortical inhibition in medication overuse headache.
Curra, Antonio; Coppola, Gianluca; Gorini, Manuela et al

in Cephalalgia : An International Journal of Headache (2011), 31(12), 1282-90

BACKGROUND: We investigated whether chronic headache related to medication overuse (MOH) is associated with changes in brain mechanisms regulating inhibitory cortical responses compared with healthy ... [more ▼]

BACKGROUND: We investigated whether chronic headache related to medication overuse (MOH) is associated with changes in brain mechanisms regulating inhibitory cortical responses compared with healthy volunteers and episodic migraineurs recorded between attacks, and whether these changes differ according to the drug overused. SUBJECTS AND METHODS: We studied 40 MOH patients whose symptoms were related to triptans alone, non-steroidal anti-inflammatory drugs (NSAIDs) or both medications combined, 12 migraineurs and 13 healthy volunteers. We used high-intensity transcranial magnetic stimulation over the primary motor cortex to assess the silent period from contracted perioral muscles. RESULTS: In MOH patients the cortical silent period differed according to the type of headache medication overused: in patients overusing triptans alone it was shorter than in healthy volunteers (44.7 +/- 14.2 vs. 108.1 +/- 30.1 ms), but similar to that reported in migraineurs (59.9 +/- 30.4 ms), whereas in patients overusing NSAIDs alone or triptans and NSAIDs combined duration of silent period was within normal limits (80.6 +/- 46.4 and 103.8 +/- 47.2 ms). CONCLUSIONS: Compared with episodic migraineurs, MOH patients overusing triptans have no significant change in cortical inhibition, whereas those overusing NSAIDs have an increase in cortical inhibitory mechanisms. We attribute these changes to medication-induced neural adaptation promoted by changes in central serotonin neurotransmission. [less ▲]

Detailed reference viewed: 10 (0 ULg)
Full Text
Peer Reviewed
See detailFactors predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate.
Schoenen, Jean ULg; Reuter, Uwe; Diener, Hans*-Christoph et al

in Cephalalgia : An International Journal of Headache (2010), 30(11), 1290-5

INTRODUCTION: Demographic and clinical variables were examined in a post hoc analysis of the PROlonged Migraine Prevention with Topiramate (PROMPT) study to determine potential contribution to relapse ... [more ▼]

INTRODUCTION: Demographic and clinical variables were examined in a post hoc analysis of the PROlonged Migraine Prevention with Topiramate (PROMPT) study to determine potential contribution to relapse. METHODS: After a six-month open-label (OL) topiramate phase, patients were randomised to continue topiramate or switch to placebo in a six-month double-blind (DB) phase. 'Relapse' was investigated in terms of change in monthly migraine days after randomisation compared with the month before randomisation, and was analysed during the first ('initial relapse') and last month ('sustained relapse') of the DB phase. More than 40 potential predicting factors were entered into analyses of variance and covariance. RESULTS: For initial relapse, variable-by-treatment interactions were significant for the Headache Impact Test (HIT-6) at DB baseline, and decline in acute medication intake or reporting of 'anxiety' in the OL phase. For sustained relapse, no statistically significant interactions were observed. CONCLUSION: Relapse after topiramate discontinuation in migraine prophylaxis appears to be unaffected by patient characteristics or baseline migraine frequency. [less ▲]

Detailed reference viewed: 18 (3 ULg)
Full Text
Peer Reviewed
See detailAlmotriptan efficacy in migraine with allodynia: a rebuttal to Burstein and Jakubowski's critique of Schoenen et al.
Schoenen, Jean ULg; Vandenheede, Michel

in Cephalalgia : An International Journal of Headache (2010), 30(9), 1147-8

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailBotulinum toxin in headache treatment: finally a promising path?
Schoenen, Jean ULg

in Cephalalgia : An International Journal of Headache (2010), 30(7), 771-3

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailMitochondrial DNA haplogroups influence response to Riboflavin in Migraineurs
Di Lorenzo, C.; Coppola, G.; Santorelli, F. et al

in Cephalalgia : An International Journal of Headache (2009, January), 29(1),

Detailed reference viewed: 28 (5 ULg)
Full Text
Peer Reviewed
See detailOccipital nerve stimulation for drug-resistant chronic cluster headache: long term follow-up up to 3 years
Gérardy, Pierre-Yves ULg; Magis, Delphine ULg; Allena, M. et al

in Cephalalgia : An International Journal of Headache (2009, January), 29(1),

Detailed reference viewed: 90 (19 ULg)
Full Text
Peer Reviewed
See detailTonabersat, a gap-junction modulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine.
Silberstein, S. D.; Schoenen, Jean ULg; Gobel, H. et al

in Cephalalgia : An International Journal of Headache (2009), 29 Suppl 2

Tonabersat is a novel benzopyran derivative that blocks the cortical spreading depression proposed to be associated with migraine attacks. The ability of single oral doses of 15, 25, 40 and 80 mg of ... [more ▼]

Tonabersat is a novel benzopyran derivative that blocks the cortical spreading depression proposed to be associated with migraine attacks. The ability of single oral doses of 15, 25, 40 and 80 mg of tonabersat to relieve the symptoms of moderate to severe migraine was evaluated in 859 migraineurs enrolled in two dose-ranging, double-blind, randomized, placebo-controlled, parallel-group trials, one international and the other North American. In the international study, significantly more patients given tonabersat than given placebo experienced relief of headache pain at 2 h (15 mg, 36.8%; 40 mg, 40.7%), the principal efficacy variable, and at 4 h (40 mg, 63.0%) and complete abolition of headache at 4 h (40 mg, 34.3%). None of the primary or secondary efficacy variables indicated significant differences between tonabersat and placebo in the North American study. Tonabersat was generally well tolerated, with dizziness and nausea the most common side-effects. Serious adverse events were uncommon, and no patient withdrew from either study because of adverse events. These results suggest a possible interplay between tonabersat pharmacokinetics (the relatively long time required to reach maximum plasma concentrations) and patient characteristics (previous triptan exposure) in the management of acute migraine attacks. Based on the pharmacokinetics and actions on cortical spreading depression, tonabersat may have potential value in migraine prophylaxis. [less ▲]

Detailed reference viewed: 29 (1 ULg)
Full Text
Peer Reviewed
See detailGlossopharyngeal neuralgia triggered by non-noxious stimuli at multiple cephalic and extracephalic sites.
ter Berg, J. W. M.; Dupont, P.; Schoenen, Jean ULg

in Cephalalgia : An International Journal of Headache (2009), 29(11), 1174-9

Glossopharyngeal neuralgia (GN) triggered by non-noxious stimuli at multiple cephalic and extracephalic sites with positron emission tomography (PET) evidence for involvement of the upper brainstem has ... [more ▼]

Glossopharyngeal neuralgia (GN) triggered by non-noxious stimuli at multiple cephalic and extracephalic sites with positron emission tomography (PET) evidence for involvement of the upper brainstem has never been reported. We present such a patient, a 73-year-old man who since the age of 50 had suffered from GN with a high recurrence rate and very severe unilateral, non-familial GN episodes with very easy trigger zones widely extending beyond the n IX territory. Extensive neuroimaging and neurophysiological tests detected no precise underlying cause. PET scan revealed activation in the upper brainstem on extracephalic triggers. Single-fibre electromyography data will be discussed. We hypothesize that deficient inhibition as seen in trigeminal nociceptive reflexes on the level of brainstem interneurons, a functional lesion in the primary somatosensory cortex-sensory thalamic nuclei circuit and the dorsal column-thalamic pathway both activated by light touch may in part be involved in the extracephalic triggering. [less ▲]

Detailed reference viewed: 49 (0 ULg)
Full Text
Peer Reviewed
See detailProposals for new standardized general diagnostic criteria for the secondary headaches.
Olesen, J.; Steiner, T.; Bousser, M.-G. et al

in Cephalalgia : An International Journal of Headache (2009), 29(12), 1331-6

Headache classification is a dynamic process through clinical testing and re-testing of current and proposed criteria. After publication of the second edition of the International Classification of ... [more ▼]

Headache classification is a dynamic process through clinical testing and re-testing of current and proposed criteria. After publication of the second edition of the International Classification of Headache Disorders (ICHD-II), need arose for revisions in the classification of medication overuse headache and chronic migraine. These changes made apparent a further need for broader revisions to the standard formulation of diagnostic criteria for the secondary headaches. Currently, the fourth criterion makes impossible the definitive diagnosis of a secondary headache until the underlying cause has resolved or been cured or greatly ameliorated by therapy, at which time the headache may no longer be present. Given that the main purpose of diagnostic criteria is to enable a diagnosis at the onset of a disease in order to guide treatment, this is unhelpful in clinical practice. In the present paper we propose maintaining a standard approach to the secondary headaches using a set of four criteria A, B, C and D, but we construct these so that the requirement for resolution or successful treatment is removed. The proposal for general diagnostic criteria for the secondary headaches will be entered into the internet-based version of the appendix of ICHD-II. During 2009 the Classification Committee will apply the general criteria to all the specific types of secondary headaches. These, and other changes, will be included in a revision of the entire classification entitled ICHD-IIR, expected to be published in 2010. ICHD-IIR will be printed and posted on the website and will be the official classification of the International Headache Society. Unfortunately, it will be necessary to translate ICHD-IIR into the many languages of the world, but the good news is that no major changes to the headache classification are then foreseen for the next 10 years. Until the printing of ICHD-IIR, the printed ICHD-II criteria remain in place for all other purposes. We issue a plea to the headache community to use and study these proposed general criteria for the secondary headaches in order to provide more evidence for their utility-before their incorporation in the main body of the classification. [less ▲]

Detailed reference viewed: 32 (4 ULg)